An observational study in Fibromyalgia, sponsored by Bilecik Seyh Edebali Universitesi. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Bilecik Seyh Edebali Universitesi · Observational
This study aims to reveal the effects of pain catastrophizing, psychological resilience, and illness perception on the impact level of fibromyalgia in patients with fibromyalgia, to determine the predictive power of these psychosocial variables regarding the impact level of fibromyalgia, and to evaluate their roles in explaining the burden of the disease.
While pain catastrophizing, resilience, and illness perception have been examined separately in patients with fibromyalgia, studies evaluating the extent to which these variables collectively predict the impact of the disease are limited. Addressing pain catastrophizing and negative illness perception as risk factors, alongside resilience as a protective factor, within a single model will contribute to a more holistic explanation of the disease burden experienced by fibromyalgia patients. The results of this study are expected to enhance the understanding of the psychosocial factors that determine the impact of the disease on fibromyalgia patients. Furthermore, the findings are anticipated to provide a scientific basis for the development of psychoeducation, cognitive-behavioral counseling, resilience-supporting interventions, and individualized care plans by nurses and other healthcare professionals. In this regard, the study will contribute to strengthening the biopsychosocial approach to fibromyalgia management and to the planning of patient-centered care practices.
Patients diagnosed with fibromyalgia
Exclusion Criteria:
Visual Analog Scale
VAS (Visual Analog Scale): A scale consisting of a 10 cm horizontal line marked at equal intervals, with one end representing "no pain" and the other "unbearable pain." The patient is asked to mark the point on the line that best represents the intensity of their pain. This distance, measured in millimeters, is interpreted as a "score." Regarding pain intensity, a score of 0 is rated as "no pain," while a score of 10 is rated as "unbearable, worst possible pain."
Time frame: 1 days
Revised Fibromyalgia Impact Questionnaire
Revised Fibromyalgia Impact Questionnaire (FIQR): This questionnaire was updated by Bennett et al. in 2009. It consists of 21 separate questions, all rated on a scale of 0 to 10; a score of 10 represents the worst possible state, while 0 indicates the absence of the complaint. The questionnaire comprises three sub-dimensions: "function" (9 questions), "overall impact" (2 questions), and "symptoms" (10 questions). The total score for function (range 0-90) is divided by 3, the total score for overall impact (range 0-20) remains unchanged, and the total score for symptoms (range 0-100) is divided by 2. The total questionnaire score (0-100) is the sum of these values. A higher score indicates a high level of impact from the disease. The recommended cut-off points for disease severity are as follows: 0-23, remission; 24-40, mild disease; 41-63, moderate disease; 64-82, severe disease; and 83-100, very severe disease. The Cronbach's alpha for the FIQR is 0.95, and item-total correlations ra
Time frame: 1 days
The Pain Catastrophizing Scale
The Pain Catastrophizing Scale is a 13-item self-report scale developed by Sullivan et al. to assess the extent to which individuals tend to catastrophize in response to pain; it utilizes a 5-point Likert-type rating system (scoring 0-4). The original form of the scale comprises three sub-dimensions: helplessness, magnification, and rumination. The internal consistency reliability of the Turkish adaptation of the Pain Catastrophizing Scale was found to be very high, with a Cronbach's alpha coefficient of 0.955. Item-total and inter-item correlation coefficients for the scale were determined to range between 0.488 and 0.848.
Time frame: 1 days
Brief Illness Perception Questionnaire
Brief Illness Perception Questionnaire: Developed by Broadbent et al. in 2006. This scale comprises 8 items plus an additional item investigating causal factors. With the exception of the ninth item regarding causal factors, the eight items on the scale use a Likert-type scoring system ranging from 0 to 10. The first five items assess cognitive illness representations: consequences (Item 1), timeline (Item 2), personal control (Item 3), treatment control (Item 4), and identity (Item 5). Two items assess emotional illness perceptions: concern (Item 6) and emotions (Item 8). One item evaluates illness coherence (Item 7). Causal representation is assessed via an open-ended question asking patients to list the most important causal factors of their illness (Item 9). Scores on the scale indicate the perceived threat of the illness or the individual's level of ease regarding the condition. When calculating the score, the values for items 3, 4, and 7 are reversed and added to the scores of
Time frame: 1 days
Brief Resilience Scale
Brief Resilience Scale: This scale was developed by Smith et al. (2008) to measure individuals' psychological resilience. It is a 6-item, self-report instrument using a 5-point Likert scale. Items 2, 4, and 6 are reverse-coded. After reversing the scores for these items, high total scores indicate a high level of psychological resilience. The internal consistency reliability of the Turkish adaptation of the scale was found to be .83.
Time frame: 1 days
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bilecik Seyh Edebali Universitesi